VFEND 50 MG FILM-COATED TABLETS

Country: ইস্রায়েল

ভাষা: ইংরেজি

সূত্র: Ministry of Health

এখন এটা কিনুন

সক্রিয় উপাদান:

VORICONAZOLE

থেকে পাওয়া:

PFIZER PFE PHARMACEUTICALS ISRAEL LTD

এটিসি কোড:

J02AC03

ফার্মাসিউটিকাল ফর্ম:

FILM COATED TABLETS

রচনা:

VORICONAZOLE 50 MG

প্রশাসন রুট:

PER OS

প্রেসক্রিপশন টাইপ:

Required

Manufactured by:

R - PHARM GERMANY GMBH

Therapeutic group:

VORICONAZOLE

Therapeutic area:

VORICONAZOLE

থেরাপিউটিক ইঙ্গিত:

Treatment of:- invasive aspergillosis, - fluconazole-resistant serious invasive Candida infections (including C. krusei)- serious fungal infections caused by scedosporium spp. and fusarium spp.- Vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - Treatment of candidemia in non neutropenic patients.- Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.

অনুমোদন তারিখ:

2013-11-11

তথ্য লিফলেট

                                [לוגו מדינת ישראל] [http://www.gov.il/]
[http://www.gov.il/] [לוגו משרד הבריאות] [לוגו משרד
הבריאות] [*5400]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
הציבור הרחב עסקים ומוסדות עובדים
בבריאות חפש מידע
תפריט	*
[סגירה]
סגור	*
דף הבית [http://www.health.gov.il/]	*
אודות	*
אודות המשרד
[http://www.health.gov.il/About/Pages/about_us.aspx]	*
תוכנית עבודה
[http://www.health.gov.il/About/Pages/Agenda.aspx]	*
תקציב המשרד
[http://www.health.gov.il/About/Pages/budget.aspx]	*
תרשים מבנה ארגוני
[http://www.health.gov.il/About/Pages/OrganizationalStructureDiagram.aspx]	*
בעלי תפקידים
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx]	*
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx]	*
לשכות הבריאות
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx?tab=3]	*
אמנת שירות
[http://www.health.gov.il/About/sla/Pages/default.aspx]	*
אותות ופרסים
[http://www.health.gov.il/About/Awards/Pages/mifal.aspx]	*
פרוייקטים תשתיתיים
[http://www.health.gov.il/About/projects/shared_medical_info/Pages/default.aspx]	*
דרושים
[http://www.health.gov.il/About/Careers/Pages/default.aspx]	*
מנכ"לי משרד הבריאות לדורותיהם
[http://www.health.gov.il/About/Pages/GeneralManegerHistory.aspx]	*
יחידות המשרד	*
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx]	*
לשכות הבריאות
[http://www.health.gov.il/UnitsOffice/LB/Pages/default.aspx]	*
וועדות ומועצות
[http://www.health.gov.il/Services/Committee/Pages/CommitteeList.aspx]	*
נושאים	*
בריאות הנפש
[http://www.health.gov.il/Subjects/mental_health/Pages/default.aspx]	*
בריאות הסביבה
[http://www.health.gov.il/Subjects/Environmental_Health/
                                
                                সম্পূর্ণ নথি পড়ুন
                                
                            

পণ্য বৈশিষ্ট্য

                                VFEND IV, POS & Film-Coated Tablets LPD CC 10 Novmber 2021
2020-0065736; 2020-0065737 2021-0067528
1
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
VFEND
®
200 mg Powder for Solution for Infusion
VFEND
®
50 mg Film-Coated Tablets
VFEND
®
200 mg Film-Coated Tablets
VFEND
®
40 mg/mL Powder for Oral Suspension
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
_VFEND Powder for solution for infusion: _
Each vial contains 200 mg of voriconazole.
After reconstitution, each ml contains 10 mg of voriconazole. Once
reconstituted further dilution is
required before administration.
Excipients with known effect
Each vial contains 221 mg sodium.
Each vial contains 3,200 mg cyclodextrin.
_VFEND Film-coated tablets: _
Each tablet contains 50 mg or 200 mg voriconazole.
Excipient with known effect
Each 50 or 200 mg tablet contains 62.5 or 250.0 mg lactose monohydrate
respectively.
_VFEND Powder for oral suspension: _
Each ml of oral suspension contains 40 mg of voriconazole when
reconstituted with water. Each bottle
contains 3 g of voriconazole.
Excipient with known effect:
Each ml of suspension contains 0.54 g sucrose.
Each ml of suspension contains 2.40 mg sodium benzoate.
FOR THE FULL LIST OF EXCIPIENTS, SEE SECTION 6.1.
3. PHARMACEUTICAL FORM
_VFEND Powder for solution for infusion: _
Powder for solution for infusion is a white lyophilised powder
containing nominally 200 mg
voriconazole presented in a 30 ml clear glass vial.
_VFEND Film-coated tablets: _
VFEND 50 mg film-coated tablets are white to off-white, round tablets,
debossed “Pfizer” on one side
and “VOR50” on the reverse.
VFEND 200 mg film-coated tablets are white to off-white,
capsule-shaped tablets, debossed “Pfizer” on
one side and “VOR200” on the reverse.
_VFEND Powder for oral suspension: _
Powder for oral suspension is a white to off-white powder providing a
white to off-white opaque fluid
containing undissolved solids when constituted.
VFEND IV, POS & Film-Coated Tablets LPD CC 10 Novmber 2021
2020-0065736; 2020-0065737 2021-
                                
                                সম্পূর্ণ নথি পড়ুন
                                
                            

অন্যান্য ভাষায় নথি

তথ্য লিফলেট তথ্য লিফলেট আরবী 06-10-2021
তথ্য লিফলেট তথ্য লিফলেট হিব্রু 15-12-2021

এই পণ্য সম্পর্কিত সতর্কতা অনুসন্ধান করুন

দস্তাবেজ ইতিহাস দেখুন